Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861874 · ClinicalTrials.gov registry record · Phase 1
A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00861874 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 13 participants.
The verdict
NCT00861874, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and feasibility of the combination of decitabine given at a fixed dose with escalating doses of rapamycin in patients with relapsed or refractory acute myeloid leukemia.
Interventions
- DRUG Decitabine
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00861874
The ClinicalTrials.gov registry entry for NCT00861874 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT00861874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00861874 about?
NCT00861874 is a clinical study titled "A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia". The purpose of this study is to determine the safety and feasibility of the combination of decitabine given at a fixed dose with escalating doses of rapamycin in patients with relapsed or refractory acute myeloid leukemia.
What is the current status of trial NCT00861874?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2010-01.
What interventions are being tested in trial NCT00861874?
The interventions under investigation include: Decitabine (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT00861874?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.